[1] Keeson EM,
Allardice GM,
George WD,
Burns HJ,
Morrison DS.
Effects of multidisciplinary team working on breast cancer survival: retrospective,
comparative,
interventional cohort study of 13722 patients.
BMJ; 2012;344:e2718
[2] Macaskill EJ,
Renshaw L,
Dixon JM: Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Oncologist 2006;11:1081–1088
.
[3]Diab SG,
Elledge RM,
Clark GM.
Tumor characteristics and clinical outcome of elderly women with breast cancer.
J Natl Cancer Inst 2000; 92:550.
[4] Quiroga-Garcia V,
Cirauqui-Cirauqui B,
Bugés-Sánchez C et al.
Primary hormone therapy in elderly women with hormone-sensitive locoregional breast cancer: endocrine therapy alone is a reasonable alternative in selected patients.
Breast Care 2015;10:179-183
[5]Extermann M,
Aapro M.
Assessment of the older cancer patient.
Hematol Oncol Clin North Am 2000; 14:63.
[6]Goodwin JS,
Hunt WC,
Samet JM.
Determinants of cancer therapy in elderly patients.
Cancer 1993; 72:594.
[7] Drãgãnescu M,
Carmocan C.
Hormone Therapy in Breast Cancer.
Chirurgia; 2017; 112(4):413-417.
[8]Balakrishnan A,
Ravichandran D.
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Br J Cancer 2011; 105:1825.
+
[9]Wink CJ,
Woensdregt K,
Nieuwenhuijzen GA,
et al.
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Ann Surg Oncol 2012; 19:1185.
[10] Michaels AY,
Keraliya AR,
Tirumani SH,
Shinagare AB,
Ramaiya HN.
Systemic treatment in breast cancer: a primer for radiologists.
Insights Imaging 2016; 7:131–144